ARTICLES

Filter  
Active filters 0
Remove
  

Refine your searches by:

Collections
Education
Social Sciences
Law
Economy
Religion
History
Research
Architecture and Urbanism
Literature
Languages
all records (75)

Languages
Spanish
English
Portuguese
German
French

Countries
Indonesia
Spain
USA
Brazil
Chile
Argentina
Colombia
Cuba
Peru
South Africa
all records (71)

Years
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
all records (24)

Filter  
 
1.923.288  Articles
1 of 192.330 pages  |  10  records  |  more records»
Aims: Liraglutide has been shown to reduce cardiovascular mortality in a cardiovascular safety study, but it is not known to what extent these results will be replicated in real practice with people with diabetes treated with liraglutide in the UK. We wis... see more

Background: Liraglutide may be less effective in patients with more advanced type 2 diabetes. This study from the Association of British Clinical Diabetologists Nationwide Liraglutide Audit analysed changes in HbA1c of patients after 26 weeks of trea... see more

People with type 2 diabetes mellitus experience an increased prevalence of non-alcoholic fatty liver disease (NAFLD) compared with the general population and often with worse outcomes. As part of the ABCD Liraglutide Nationwide Audit Programme, we obtaine... see more

Introduction: People with type 2 diabetes are known to be at increased risk of non-alcoholic fatty liver disease (NAFLD). There is increasing evidence of diabetes treatments with benefits of also improving NAFLD. Although mostly focused on glucagon-l... see more

Introduction: Evidence from phase III and the EMPA-REG OUTCOME trials have demonstrated improvements in renal endpoints with empagliflozin use. The EMPA-KIDNEY trial is currently underway and is assessing whether there are benefits of empagliflozin i... see more

We describe the rationale, aims and objectives and the methodology of data collection for the ABCD nationwide audit of individuals admitted to hospital with coronavirus (SARS-CoV-2; COVID-19) and diabetes. The audit was inspired and undertaken by the urge... see more

Introduction: Canagliflozin was initially approved for use in the UK in March 2013. Randomised control trial evidence has demonstrated multiple beneficial effects. Many of these are present at initial follow-up and within 26 weeks of randomised contr... see more

Injectable glucagon-like peptide-1 receptor agonists (GLP-1ras) have the distinct advantage of promoting weight loss as well as lowering glucose in type 2 diabetes. Treatment with a GLP-1ra is costly, thereby necessitating a restriction on widespread use,... see more

The purpose of this paper is to discuss a Christian teacher’s calling in response to the great commission of Jesus Christ in building character in digital era. The main task of a teacher in the context of Christian education is to assist students in knowi... see more

1 of 192.330 pages  |  10  records  |  more records»